ATE451451T1 - Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen - Google Patents

Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen

Info

Publication number
ATE451451T1
ATE451451T1 AT97934948T AT97934948T ATE451451T1 AT E451451 T1 ATE451451 T1 AT E451451T1 AT 97934948 T AT97934948 T AT 97934948T AT 97934948 T AT97934948 T AT 97934948T AT E451451 T1 ATE451451 T1 AT E451451T1
Authority
AT
Austria
Prior art keywords
rsv
mutations
attenuated
recombinant
vaccines
Prior art date
Application number
AT97934948T
Other languages
English (en)
Inventor
Brian Murphy
Peter Collins
Stephen Whitehead
Alexander A Bukreyev
Katalin Juhasz
Michael Teng
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE451451T1 publication Critical patent/ATE451451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT97934948T 1996-07-15 1997-07-15 Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen ATE451451T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2177396P 1996-07-15 1996-07-15
US4614197P 1997-05-09 1997-05-09
US4763497P 1997-05-23 1997-05-23
PCT/US1997/012269 WO1998002530A1 (en) 1996-07-15 1997-07-15 Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Publications (1)

Publication Number Publication Date
ATE451451T1 true ATE451451T1 (de) 2009-12-15

Family

ID=27361727

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934948T ATE451451T1 (de) 1996-07-15 1997-07-15 Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen

Country Status (12)

Country Link
US (2) US5993824A (de)
EP (2) EP0912724B1 (de)
JP (2) JP4413999B2 (de)
KR (2) KR100894670B1 (de)
CN (1) CN101012454B (de)
AT (1) ATE451451T1 (de)
AU (1) AU3799797A (de)
BR (2) BR9710363A (de)
CA (1) CA2257823A1 (de)
DE (1) DE69739689D1 (de)
ES (1) ES2345643T3 (de)
WO (1) WO1998002530A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US7485440B2 (en) * 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
ATE451451T1 (de) * 1996-07-15 2009-12-15 Us Gov Health & Human Serv Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
AU739597B2 (en) * 1997-05-02 2001-10-18 Uab Research Foundation, The Attenuation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
WO1999015672A1 (en) * 1997-09-19 1999-04-01 American Cyanamid Company Attenuated respiratory syncytial viruses
US20100028377A1 (en) * 1997-09-26 2010-02-04 Medimmune, Llc Recombinant RSV Virus Expression Systems And Vaccines
AU2006200619B2 (en) * 1997-09-26 2007-12-13 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6830748B1 (en) * 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
US6908618B2 (en) 1997-11-10 2005-06-21 University Of Maryland Production of novel bovine respiratory syncytial viruses from cDNAs
DK2316923T3 (en) 1998-06-12 2018-01-08 Icahn School Med Mount Sinai Attenuated influenza viruses with altered interferon antagonist activity for use as vaccines and drugs
EP1098961B1 (de) 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon induzierende genetisch veränderte attenuierte viren
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
BR0011159A (pt) * 1999-04-13 2002-07-23 Government Of The Us Dept Of H Método para produzir vacinas de vìrus rna de fita negativa atenuado a partir de sequências de nucleotìdeos clonados
MXPA01010320A (es) 1999-04-13 2003-09-15 Us Health Produccion de vacunas con virus sincitial respiratorio quimerico atenuado a partir de secuencias nucleotidas clonadas.
CN101260386A (zh) * 1999-07-09 2008-09-10 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
CN101392239A (zh) 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
CN1384883A (zh) * 1999-07-13 2002-12-11 美国政府健康及人类服务部 表达免疫调节分子的重组呼吸道合胞病毒的制备
CN1367839A (zh) * 1999-09-06 2002-09-04 株式会社载体研究所 含有已改变的转录起始序列的副粘病毒
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) * 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
EP1297110B1 (de) * 2000-06-23 2009-07-22 Intervet International BV Attenuiertes bovines respiratorisches syncytialvirus
DE60136811D1 (de) * 2000-06-23 2009-01-15 Us Gov Health & Human Serv Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren
WO2002030457A2 (en) * 2000-10-12 2002-04-18 Washington University In St. Louis Microbes having an attenuating mutation comprising a transcription terminator
AU2002236522B2 (en) * 2000-11-28 2007-10-25 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
KR101105984B1 (ko) 2001-01-19 2012-01-18 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
UA82466C2 (uk) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
AU2002327755A1 (en) * 2001-09-28 2003-04-14 Rush-Presbyterian-St. Luke's Medical Center Paramyxoviruses as gene transfer vectors to lung cells
ATE509097T1 (de) 2001-11-21 2011-05-15 Us Health Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
CA2743750A1 (en) 2002-02-21 2003-09-04 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus
CN1678345A (zh) 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1572947B1 (de) 2002-09-18 2014-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services GEWINNUNG VON REKOMBINANTEM HUMANEM PARAINFLUENZA-VIRUS TYP 2 (HPIV2) AUS cDNA UND VERWENDUNG VON REKOMBINANTEM HPIV2 IN IMMUNOGENEN ZUSAMMENSETZUNGEN SOWIE ALS VEKTOREN ZUR HERVORRUFUNG VON IMMUNREAKTIONEN GEGEN PIV UND ANDERE MENSCHLICHE KRANKHEITSERREGER
WO2004041838A1 (en) * 2002-11-01 2004-05-21 University Of Massachusetts Regulation of transcription elongation factors
AU2004262624B2 (en) 2003-02-28 2009-11-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
EP1623006A4 (de) 2003-04-25 2009-10-28 Medimmune Vaccines Inc Metapneumovirus-stämme und ihre verwendung in impfstofformulierungen und als vektoren zur expression antigener sequenzen sowie verfahren zur viruspropagierung
AU2004249133B2 (en) 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
KR101020532B1 (ko) 2003-06-09 2011-03-09 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의 회수를 위한 개선된 방법
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
EA011878B1 (ru) 2003-12-24 2009-06-30 Де Стат Дер Недерланден, Вертегенвордигд Дор Де Министер Ван Волксгезондхейд, Велзейн Ен Спорт Респираторно-синцитиальный вирус с перекрестно компенсированным геномным дефицитом
EP1766059B1 (de) 2004-05-25 2012-07-11 MedImmune Vaccines, Inc. Influenza-hämagglutinin- und neuraminidase-varianten
US8124101B2 (en) 2004-06-01 2012-02-28 Mount Sinai School Of Medicine Genetically engineered swine influenza virus and uses thereof
EP1828421A2 (de) * 2004-11-16 2007-09-05 Janssen Pharmaceutica N.V. Sphingosine-kinase-1- bedingte gen-expressionsregulation eines chemoattraktanten monozyten-protein-1-gens
EP1814990A2 (de) 2004-11-19 2007-08-08 Wisconsin Alumni Research Foundation Rekombinante influenza-vektoren mit transkriptionseinheiten, die in tandem vorliegen
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP2251034B1 (de) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimäre newcastle disease viren zur präsentation von nicht -nativen oberflächenproteinen und deren verwendung
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
AU2007286161B2 (en) 2006-08-09 2013-05-02 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US9476032B2 (en) 2007-03-30 2016-10-25 The Research Foundation For The State University Of New York Attenuated viruses useful for vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2069484B1 (de) 2007-06-18 2014-08-13 MedImmune, LLC Influenza-B-Viruses mit verändertem Hämagglutininpolypeptid
WO2009012155A2 (en) * 2007-07-13 2009-01-22 Medimmune, Llc Preparation of negative-stranded rna viruses by electroporation
US20110189232A1 (en) * 2008-07-01 2011-08-04 The Government Of The United States Of America Represented By The Secretary RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1
US8591914B2 (en) 2008-07-11 2013-11-26 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP5644502B2 (ja) 2008-11-05 2014-12-24 旭硝子株式会社 含フッ素弾性共重合体、その製造方法および架橋ゴム
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
SG2014010185A (en) 2009-02-12 2014-06-27 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US8597637B1 (en) * 2010-05-18 2013-12-03 Weidong Zhang Breast cancer therapy using an engineered respiratory syncytial virus
US9044499B1 (en) 2010-06-22 2015-06-02 Weidong Zhang NS1/2-deficient respiratory syncytial virus and melanoma treatment
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
US9624475B2 (en) 2012-04-13 2017-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically stable live attenuated respiratory syncytial virus vaccine and its production
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
HRP20230694T1 (hr) * 2013-02-08 2023-10-13 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para
CN113322264B (zh) 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CN103789276B (zh) * 2014-01-14 2015-12-09 昆明理工大学 一种呼吸道合胞病毒减毒毒株及其应用
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
JP6336044B2 (ja) * 2014-04-10 2018-06-06 株式会社Ｊｏｌｅｄ 有機ｅｌ表示パネルの製造方法
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016118642A1 (en) 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
BR112017015789A2 (pt) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus da influenza suína bivalente
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2017031408A1 (en) 2015-08-20 2017-02-23 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
WO2017031401A2 (en) 2015-08-20 2017-02-23 University Of Rochester Ns1 truncated virus for the development of canine influenza vaccines
AU2016308917A1 (en) 2015-08-20 2018-03-15 Cornell University Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
MX388635B (es) 2016-06-03 2025-03-20 Univ Rochester Vacunas atenuadas vivas del virus de la influenza equina
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
JP7198759B2 (ja) 2016-09-23 2023-01-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107384958B (zh) * 2017-07-14 2020-04-10 北京交通大学 基于反向遗传学构建的rsv反基因组质粒及其应用
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
MX2020008927A (es) 2018-02-27 2021-01-08 Univ Rochester Vacuna contra la influenza atenuada viva multivalente para la prevencion y el control del virus de la influenza equina (eiv) en caballos.
SG11202008225PA (en) 2018-04-17 2020-11-27 Curevac Ag Novel rsv rna molecules and compositions for vaccination
EP3810634A4 (de) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaik-influenzavirus-hämagglutinin-polypeptide und deren verwendungen
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
EP3914295A2 (de) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutationen zur verleihung von genetischer stabilität gegenüber zusätzlichen genen bei grippeviren
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
EP3930749A1 (de) 2019-02-27 2022-01-05 University of Rochester Multivalenter abgeschwächter influenza-lebendimpfstoff zur vorbeugung und kontrolle des equinen influenzavirus (eiv) bei pferden
EP3959216A4 (de) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai Neuraminidase-antikörper gegen influenza-b-virus und verwendungen davon
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function
CN119709863B (zh) * 2024-12-20 2025-09-30 中国疾病预防控制中心病毒病预防控制所 Rsv-ba9基因型变异株感染性克隆的构建及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
EP1394259A3 (de) * 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US20030054505A1 (en) 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
ATE181112T1 (de) * 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
BR9610590A (pt) 1995-09-22 2000-10-24 Connaught Lab Glicoproteìnas e vacinas de vìrus parainfluenza
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US5869036A (en) 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US6077514A (en) 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
ATE451451T1 (de) 1996-07-15 2009-12-15 Us Gov Health & Human Serv Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CN1250725C (zh) 1997-05-23 2006-04-12 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法
JP4434478B2 (ja) 1997-07-11 2010-03-17 イエール ユニバーシティー リエンジニアリングされた外被を有するラブドウイルス
US6364957B1 (en) 1997-10-09 2002-04-02 Applied Materials, Inc. Support assembly with thermal expansion compensation
WO1999024564A1 (en) 1997-11-10 1999-05-20 University Of Maryland PRODUCTION OF NOVEL BOVINE RESPIRATORY SYNCYTIAL VIRUSES FROM cDNAs
BR0011159A (pt) 1999-04-13 2002-07-23 Government Of The Us Dept Of H Método para produzir vacinas de vìrus rna de fita negativa atenuado a partir de sequências de nucleotìdeos clonados
MXPA01010320A (es) 1999-04-13 2003-09-15 Us Health Produccion de vacunas con virus sincitial respiratorio quimerico atenuado a partir de secuencias nucleotidas clonadas.
WO2001004321A1 (en) 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of m2 orf2
CN1384883A (zh) 1999-07-13 2002-12-11 美国政府健康及人类服务部 表达免疫调节分子的重组呼吸道合胞病毒的制备
US9615524B2 (en) 2015-04-17 2017-04-11 Pop Vriend Research Bv Garden bean variety PV-832

Also Published As

Publication number Publication date
EP2112220A2 (de) 2009-10-28
ES2345643T3 (es) 2010-09-28
JP2002511731A (ja) 2002-04-16
CA2257823A1 (en) 1998-01-22
DE69739689D1 (de) 2010-01-21
EP2112220A3 (de) 2010-01-06
KR100894670B1 (ko) 2009-04-22
US20060159703A1 (en) 2006-07-20
CN101012454B (zh) 2011-11-16
US7709007B2 (en) 2010-05-04
JP4413999B2 (ja) 2010-02-10
WO1998002530A1 (en) 1998-01-22
BRPI9710363B8 (pt) 2021-07-06
EP0912724B1 (de) 2009-12-09
AU3799797A (en) 1998-02-09
BRPI9710363A (pt) 2000-01-11
US5993824A (en) 1999-11-30
KR100658491B1 (ko) 2006-12-18
KR20000023802A (ko) 2000-04-25
CN101012454A (zh) 2007-08-08
BRPI9710363B1 (pt) 2011-11-16
JP2008283984A (ja) 2008-11-27
KR20060015658A (ko) 2006-02-17
EP0912724A1 (de) 1999-05-06
BR9710363A (pt) 2000-01-11

Similar Documents

Publication Publication Date Title
ATE451451T1 (de) Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
Liljeqvist et al. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
KR100850620B1 (ko) 약독된 생백신
WO2000061611A3 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
ATE181359T1 (de) Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen
FR2742756B1 (fr) Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
CA2230033A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
RU2010130338A (ru) Мутантные формы стрептолизина о
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
JP2001516583A5 (de)
Hilleman Newer directions in vaccine development and utilization
EP1323428A3 (de) Avirulente Salmonella Mikroben und ihre Verwendung
Hearn Jr et al. Cross-protection in animals infected with group A arboviruses
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
CA2430115A1 (en) Recombinant rsv virus expression systems and vaccines
WO2000034445A3 (en) Live attenuated venezuelan equine encephalitis vaccine
DK8789D0 (da) Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
WO2001010469A3 (en) Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties